GC Pharma has outlined a new R&D strategy to investors and analysts that prioritizes the development of plasma derivatives, vaccines and rare disease drugs to improve its falling research productivity.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?